Sectors:
Min Investment:
Max Investment:
Target Investment:
Total Funding: $19M
Total Funding: $12M
Total Funding: $62M
Total Funding: $3M
Total Funding: $93M
Total Funding: $34M
Total Funding: $17M
Total Funding: $6.8M
Total Funding:
2018
Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with Canada's most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices.
2022
2021
LQT Therapeutics, Inc. is pioneering a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias based on research from Beth Israel Deacons Medical Center, Massachusetts General Hospital, and Sanofi, S.A. By combining leading-edge cardiovascular genetics and diagnostics with recent advances in the understanding of the role of SGK1, LQT Therapeutics seeks to make a meaningful difference in the lives of people suffering from Long QT Syndrome and resistant cancers. LQT Therapeutics was founded by world-class experts in cardiovascular disease, cardiac muscle biology and drug development.
2021
2021
Réseau Capital, the Québec Venture Capital and Private Equity Association, is the only private equity association that brings together all stakeholders involved in the Quebec investment chain. The mission of Réseau Capital is to contribute to the development and efficient operation of the private equity industry, which plays a major role in the development and financing of businesses in Québec.
2019
2013
2013
Hacking Health is designed to improve healthcare by inviting technology creators and healthcare professionals to collaborate on realistic, human-centric solutions to front-line problems. Our hackathons and workshops are fun, intense, hands-on events where small teams tackle tough problems in a supportive community of peers and mentors.
2015 - 2023
2015 - 2023
Imagia believes that the technology of deep learning is a key to the future of medical image processing, with its ability to merge large and diverse data sources to make more accurate predictions. Deep learning is working today, and is more capable to assist physicians than ever, improving early cancer diagnosis. Imagia bridges the gap between academic research and clinical practice, making this world-changing technology accessible to improve patient care.
2011 - 2022
2011 - 2022
Profound Medical is a Canadian medical device company that has developed a unique, minimally invasive treatment to ablate the prostate gland. Profound's novel technology combines Magnetic Resonance Imaging (MRI) guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland. Delivered via a trans-urethral approach, this method of prostate cancer treatment affords highly accurate and precise treatment within the prostate gland in a short time span in an outpatient setting. The potential of this technology is currently being demonstrated in Phase I clinical trials.
2021 - 2022
2021 - 2022
Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.
2012 - 2018
2012 - 2018
Clementia is a privately-held, clinical stage biotechnology company dedicated to the development and commercialization of treatments for people living with rare diseases by exploiting the use of novel Retinoic acid receptor gamma agonists (RARγ) to address diseases of heterotopic ossification, including Fibrodysplasia Ossificans Progressiva.